tirzepatide compound for research 1 and GIP therapy takes appetite regulation and metabolism support to the next level Compounded GLP-1/GIP (Tirzepatide) - bmiMD

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

I don't want this to happen to anybody else

Create a Calm Sleep Environment : Make your bedroom comfortable by keeping it dark, quiet, and cool

Mechanism of Action Enhances glucose-dependent insulin secretion Suppresses glucagon release Delays gastric emptying Promotes satiety via central appetite regulation Pharmacokinetics Route: Subcutaneous (once weekly) Half-life: ~1 week Metabolism: Proteolytic degradation Excretion: Urine and feces Clinical Benefits HbA1c reduction of ~11.5% Significant weight loss (515%) Proven cardiovascular protection Minimal risk of hypoglycemia when used alone Adverse Effects Common: Nausea, vomiting, diarrhea Rare: Pancreatitis, gallbladder disease Contraindicated in medullary thyroid carcinoma / MEN-2 The Bigger Picture -The transition of semaglutide from a high-cost, premium therapy to an affordable mass drug represents a paradigm shift

Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)